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Abstract 
Use of the HMG-CoA Reductase Inhibitors, also known as statins, in patients with renal 
dysfunction is laden with controversy. Studies on statin use in renal patients have given 
varying reports. Some research has indicated that these medications may exacerbate 
existing renal dysfunction and induce further progression of renal disease. Furthermore, 
some researchers have suggested statins may actually cause some cases of renal 
dysfunction through the effects of rhabdomyolysis, acute interstitial nephritis, or 
necrotizing immune-mediated myopathy, while other researchers have asserted that the 
statins can have nephroprotective effects. The use of statins is believed to be ineffective 
in patients who are already in end-stage renal failure, but the research varies on this point, 
as well. There is currently a lack of researched knowledge regarding the safety and 
efficacy of HMG-CoA Reductase Inhibitors in patients with renal dysfunction, as well as 
the potential causative link between these medications and renal dysfunction. 
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Statins and Kidney Failure 
According to the latest data from the Centers for Disease Control and Prevention 
(CDC), over 20 million people in the United States (U.S.) have chronic kidney disease 
(CKD); this accounts for more than 10% of the U.S.’s adult population (Centers for 
Disease Control and Prevention, 2014b). Many of these individuals are likely to have 
elevated serum cholesterol levels, causing CKD patients to have higher rates of 
cardiovascular disease (Elliott, McCaughan & Fogarty, 2014). One of the most common 
pharmacological treatments for patients with elevated cholesterol levels is the use of 
HMG-CoA Reductase Inhibitors, also known as statin drugs. Catapano (2012, Abstract) 
named the statins as “the most widely prescribed therapeutic class of drugs worldwide.” 
Recent national statistics indicate that the use of statins in the U.S. is apparently 
increasing as more Americans are developing hypercholesterolemia and require 
pharmacological treatment (Centers for Disease Control and Prevention, 2014a).  
Statins’ Nephrotoxic Effects 
Statins generally have few adverse effects; however, they can cause myotoxicity 
in some patients, leading to muscle breakdown. According to a systematic review 
published by Ganga, Slim and Thompson (2014), about 10-25% of patients treated with 
statins in clinical practice develop muscle problems. As muscle fibers break down, a 
byproduct known as myoglobin travels to the renal system where the kidneys attempt to 
process and eliminate the myoglobin. The healthy renal system, unprepared for 
myoglobin’s large protein structure, may lose its ability to function in response to 
myoglobin accumulation in the renal glomeruli. For a renal system that is already 
damaged, as in someone with CKD, the kidneys may become even further damaged and 
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the CKD may progress to a later stage, possibly necessitating the use of renal 
replacement therapy (RRT), such as hemodialysis (HD), peritoneal dialysis (PD), or a 
renal transplant (Olyaei, Greer, Santos & Rueda, 2011). According to Auer, Sinzinger, 
Franklin and Berent (2014), renal compromise is the most common form of organ 
damage related to statin-induced myopathy. 
The most severe form of statin-related myotoxicity is rhabdomyolysis. Mendes, 
Robles and Mathur (2014) published a comprehensive review of 112 cases of 
rhabdomyolysis, asserting that statin-induced rhabdomyolysis is generally rare in most of 
the general population, and it causes approximately 0.3-13.5 cases per 1,000,000 statin 
prescriptions; however, other forms of toxicity are less rare and can result in organ 
damage. Olyaei et al. (2011) examined case studies of kidney transplant patients and 
patients with CKD who received statins, and they found that patients with preexisting 
renal problems such as CKD actually have a much higher risk of developing statin-
related myalgia, myopathy, and rhabdomyolysis than those in the general population.  
Although myopathy is a known side effect of the statin drugs, and such myopathy 
may lead to renal dysfunction, there is limited research on the incidence of statin-caused 
renal dysfunction related to myopathies other than rhabdomyolysis. Ironically, some 
research has indicated statins might have nephroprotective effects; for this reason, statin 
therapy is sometimes prescribed for patients who have an increased risk for acute kidney 
injury (AKI), a condition of renal insufficiency that can lead to renal failure and CKD. 
Statin use in patients who already have renal dysfunction is also controversial due to a 
lack of ample research on the safety and efficacy of statin use in patients who already 
have renal dysfunction with or without the need for dialysis.  
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Intended Effects of Statins 
Elevated serum cholesterol levels have long been associated with an increased 
risk for cardiovascular events, due to cholesterol’s role in atherosclerosis, a disease 
process in which artery walls thicken in response to lipid accumulation and inflammatory 
processes within the vessels. Although dietary interventions and lifestyle modifications 
are generally the recommended treatment method for hypercholesterolemia, sometimes, 
hypercholesterolemia is very severe, or it does not respond effectively to these 
interventions alone, so patients may use pharmacological therapy to treat their 
hypercholesterolemia. The first-line pharmacological therapy for elevated cholesterol is 
treatment with a statin drug (Catapano, 2012). According to the CDC (2014b), a growing 
number of people in the United States are developing hypercholesterolemia, and 
consequently use statins in an attempt to control their cholesterol levels.  
There are two ways cholesterol enters the bloodstream: through dietary, 
exogenous cholesterol and through endogenous cholesterol produced by the liver, which 
constitutes the greater part of serum cholesterol. Since cholesterol is a lipid, it cannot 
move freely in the blood. Instead, lipoproteins cover the cholesterol molecules within a 
phospholipid layer, so the cholesterol can then travel through the bloodstream to the body 
cells where it impacts essential cellular functions. High-density lipoproteins (HDLs) are a 
type of lipoprotein that consists of a high protein percentage and a low percentage of 
cholesterol, whereas low-density lipoproteins (LDLs) contain a minor protein component 
with a high cholesterol percentage. Due to their high percentage of cholesterol, LDLs are 
strongly involved in coronary atherosclerosis; thus, lowering LDL levels may actually 
reverse atherosclerotic changes in some people’s vessels. In contrast to LDLs, HDLs 
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function to remove LDL-carried cholesterol from body cells and carry it back to the liver, 
where it is metabolized and eventually eliminated from the body; thus, HDLs have 
protective effects against atherosclerosis (Mani et al., 2014). 
The effects of the statin drugs derive from the statins’ inhibition of an enzyme 
known as HMG-CoA Reductase (3-hydroxy-3-methylglutaryl coenzyme A Reductase), 
which catalyzes an essential reaction in hepatic cholesterol synthesis. Although HMG-
CoA Reductase inhibition actually increases the hepatic synthesis of HMG-CoA 
Reductase, it also causes hepatocytes to synthesize more LDL receptors, which then bind 
to LDL, and remove it from the bloodstream. Mani et al. (2014) published a retrospective 
analysis of 2,566 patients receiving statins, which suggested that by inhibiting HMG-
CoA Reductase, the statin drugs might reduce cholesterol synthesis and thereby decrease 
atherosclerotic plaque development within blood vessels. Since cholesterol is an 
independent risk factor for major cardiovascular events and mortality, statin therapy is a 
respected form of preventive treatment for cardiovascular disease (Centers for Disease 
Control and Prevention, 2014a).  
A recent study by Lee et al. (2011) examined atherectomy specimens from 22 
patients with unstable angina and 21 patients with stable angina that had undergone 
surgery due to de novo coronary artery lesions. The researchers tested the specimens for 
the presence of antibodies specific to HMG-CoA Reductase, and they found that patients 
with HMG-CoA Reductase in these plaques were much more likely to have unstable 
versus stable angina. The study revealed that when HMG-CoA Reductase is present in 
atherosclerotic plaques, this enzyme might contribute to additional cholesterol synthesis 
and make these plaques more unstable and likely to rupture. Plaque rupture often leads to 
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adverse outcomes due to myocardial infarction (MI), cerebrovascular accident (CVA), 
and other adverse cardiovascular events (Lee et al., 2011).  
Controversy over Statin’s Effects on the Kidneys 
Current research concerning statins’ effects on the renal system is rather 
inconsistent, since some studies have asserted that statins can protect against renal injury 
and AKI, whereas others have attributed cases of AKI and advanced CKD to myopathies 
caused by statins (Kostapanos, Milionis & Elisaf, 2010). Statin use in patients who have 
preexisting renal dysfunction prior to statin therapy is particularly controversial. Ahmad 
(2014) asserted that although rhabdomyolysis in the general population is somewhat rare, 
the incidence of rhabdomyolysis in patients with CKD is much higher than in the general 
population and the myopathy from statin use is also relatively common; such myopathy 
can also progress CKD in the same way that rhabdomyolysis can progress CKD. At the 
same time, statins’ effects in lowering serum cholesterol and preventing atherosclerotic 
plaque build-up might benefit the kidneys and invalidate concerns about statins’ risk. 
Statin therapy for patients with CKD requires careful consideration into their risks and 
benefits to the kidneys. 
The statin drugs may potentiate multiple effects on the kidney. Perhaps, the most 
intriguing aspect of these medications and their effects on the kidneys is the fact that they 
are neither inherently nephrotoxic, nor are they inherently nephroprotective. Part of the 
problem with determining the full extent of statin-caused renal damage derives from the 
fact that there are several different forms of muscle problems that relate to statin therapy, 
and rhabdomyolysis is only one of these. In a recent article discussing statin intolerance 
due to myopathies or high creatine kinase levels, Ahmad (2014) admitted that there is 
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still not a standardized criterion for describing or diagnosing statin intolerance. Auer et 
al. (2014) also discussed the discrepancies in clinical research studies and everyday 
practice, saying that inconsistent definitions or exclusion criteria may explain the 
inconsistent data. They described statin myopathy as being an entity with no clearly 
agree-upon definition (Auer et al., 2014).  
Statin-Induced Renal Damage 
Research has indicated that statins may be directly responsible for potentiating 
and progressing some cases of renal dysfunction. The exact mechanism by which they 
may exert nephrotoxic effects is unclear, however. Table 1 shows some relevant studies, 
detailing the methods used to collect the data, as well as the study findings.  
Table 1    Studies that suggest statins may contribute to all types of renal insufficiency 
Study/ 
Year 
Population Intervention/ 
Methods 
Comparison Outcome Time 
Data 
analysis 
by 
Murugan 
et al./ 
2012 
Patients 
hospitalize
d with 
community
-acquired 
pneumonia 
N=1,836; 
 ≥18 years 
Multicenter, 
prospective 
observational 
inception cohort 
study 
413 patients 
received statin 
therapy prior to 
hospitalization 
for pneumonia 
1,423 
patients did 
not receive 
statin 
therapy 
prior to 
hospitalizati
on for 
pneumonia 
Patients who used 
statins prior to 
hospitalization had 
an increased 
incidence of AKI 
One-
year 
follow-
up 
period 
Data 
analysis 
by Zhang 
et al./ 
2009 
Saarland 
inhabitants 
who 
participated 
in the 
ESTHER 
Study from 
July 2000 
to 
December 
Cross-sectional, 
multivariate 
analysis 
848 participants 
reported regular 
statin usage 
4,134 
participants 
reported 
having 
hypertensio
n, a known 
CKD risk 
factor 
3,977 
Statin usage was an 
independent risk 
factor for the 
presence of CKD 
Two-
year 
follow-
up 
period 
STATINS AND KIDNEY FAILURE 10 
2002 
N=9,806; 
50-74 
years; 
55% 
female 
participants 
reported 
having 
diagnosed 
hyperlipide
mia 
PLANET 
I/ 2006 
Patients 
with 
urinary 
protein/cre
atinine 
ratios of 
500-5,000 
mg/g and a 
fasting 
LDL 
cholesterol 
of ≥90 
mg/dL 
N=325 
Randomized, 
prospective 
study 
Patients in the 
experimental 
group received 
80 mg 
atorvastatin per 
day 
Patients in 
the control 
groups 
either 
received 40 
mg 
rousvastatin 
per day or 
10 mg 
rosuvastatin 
per day 
Atorvastatin use 
reduced proteinuria 
by approximately 
20%, but there was 
no effect on the rate 
of decline in 
glomerular filtration 
rate (GFR) 
Rosuvastatin did not 
affect proteinuria, 
but it decreased 
GFR by 8 
mL/minute every 
year 
Renal adverse 
reactions were 
higher with 
rousvastatin use 
52-
week 
follow-
up 
period 
As demonstrated in Table 1, Murugan et al. (2012) studied a large cohort of 1836 
patients with community-acquired pneumonia. Of the 1836 total patients studied, 413 
patients received a statin prior to their hospitalization. The purpose of the study was to 
determine if statin use decreased patients’ risk for pneumonia-induced AKI as well as 
examining whether one-year and cause-specific mortality in AKI patients decreased with 
statin therapy. As described in Table 1, the study revealed that the 413 patients who took 
a statin before coming to the hospital did not have a lower risk for AKI; however, if they 
did develop AKI, they had a slightly lower risk of death at one year. One-third of the 
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deaths in AKI patients related to cardiovascular disease. The researchers concluded that 
statin usage did not decrease the risk for AKI and did not correlate with a decreased risk 
of death at one year (Murugan et al., 2012).  
Another study by Zhang et al. (2009) that analyzed multiple variables including 
older age, cardiovascular history, DM and the use of statins concluded that statin use may 
increase the risk of CKD. The researchers included the analysis of studies such as the 
ESTHER Study (Epidemiologische Studie zu Chancen der Verhuetung, Frueherennung 
und optimierten Therapie chronischer Erkrankungen in der aelteren Bevoelkerung), 
which collected data on a large sample of patients who ranged in age from 50 to 74 years 
old and had CKD. The study revealed statistically significant increases in the incidence of 
CKD for patients who had formerly taken statins, as Table 1 further describes. The 
researchers therefore advised older adults to cautiously consider the effects of these 
medications on their renal systems (Zhang et al., 2009). 
In 2013, Olyaei et al. conducted a literature review of studies that analyzed statin 
use in patients with CKD and end-stage renal disease (ESRD). They discussed several 
newly published studies including Prospective Evaluation of Proteinuria and Renal 
Function in Diabetic Patients with Progressive Renal Disease PLANET I and PLANET 
II. In these studies groups of 325 and 220 patients respectively were selected based on the
presence of a urinary protein/creatinine ratio of 500 to 5,000 milligrams (mg) per gram 
and a fasting LDL-cholesterol level of greater than or equal to 90 mg/dL. Participants 
were divided into randomized groups that either received daily 80 mg doses of 
atorvastatin, daily 10 mg doses of rosuvastatin, or daily 40 mg doses of rousvastatin. The 
study revealed that atorvastatin therapy generally decreased participants’ incidence of 
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proteinuria; however, atorvastatin therapy did not affect the rate of GFR decline. In 
contrast, rosuvastatin causes GFR to decline by 8 milliliters per minute each year, while 
having no effect on urinary excretion of protein. Based on these results as shown in Table 
1, Olyaei et al. (2013) concluded that statin therapy for patients with CKD is complex 
and may not be as safe or effective as statin therapy in non-CKD patients. 
Possible Nephroprotective Effects 
In contrast to the studies that emphasize the potential nephrotoxic effects of the 
statins, some studies have indicated that statin medications may be useful in preventing or 
slowing renal dysfunction and may even have nephroprotective effects, especially when 
used before surgery. Surgical patients have an increased risk for developing AKI due to 
fluid loss as well as pharmacologic therapy that may be used during surgery. On some 
occasions, healthcare providers have chosen to give statin medications in an attempt to 
decrease this risk (Lee et al., 2011). The exact mechanism of nephroprotection is not 
clear; however, several clinical trials have shown a possible benefit to such prophylactic 
therapy. Below, Table 2 outlines various trial findings, describing the data collection 
methods, as well as the results.  
Table 2   Studies that suggest statins have nephroprotective effects 
Study/ 
Year 
Population Intervention/ 
Methods 
Comparison Outcome Time 
Data 
analysis 
by Layton 
et al./ 
2013 
Patients 
who 
underwent 
CABG 
surgery 
N=17,077; 
52.5-76.4 
years; 
Retrospective 
cohort study of 
CABG patients 
3,085 patients 
received statins 
<20 days prior 
to non-emergent 
CABG surgery 
Control 
group of 
13,992 
patients did 
not receive 
statins prior 
to non-
emergent 
CABG 
Statin use prior to 
non-emergent 
CABG was 
consistently linked 
with a decreased 
risk of AKI 
Data 
was 
collecte
d on a 
ten-year 
period 
from 
2000 to 
2010 
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33% 
female 
surgery 
Data 
analysis 
by 
Brunelli et 
al./ 
2012 
Patients 
who 
underwent 
major open 
abdominal, 
cardiac, 
thoracic, or 
vascular 
procedures 
N=78,100; 
43.5-75.3 
years; 
45.6% 
female 
Retrospective 
cohort study of 
surgical patients 
10,779 patients 
received at least 
one dose of 
atorvastatin, 
Fluvastatin, 
lovastatin, 
pravastatin, 
rosuvastatin, or 
simvastatin 
between 
hospital 
admission and 
surgery 
Control 
group of 
67,321 
patients did 
not receive 
statins prior 
to surgery 
Statin users had an 
18-22% reduction in 
the development of 
AKI within 72 hours 
following surgery  
High-potency statins 
seem to have more 
protective power 
against AKI 
Data 
was 
collecte
d on a 
ten-year 
period 
from 
2000 to 
2010 
Data 
analysis 
by Luk et 
al./ 
2010 
Chinese 
patients 
with type 2 
diabetes 
recruited 
between 
1996 and 
2005 
N=5,264; 
45-66 
years; 
53% 
female 
Prospective 
cohort study of 
the Hong Kong 
Diabetes 
Registry  
1,275 patients 
received statins 
3,989 
patients did 
not receive 
statins 
Statin users had a 
68% reduction in 
the incidence of 
renal dysfunction 
2.77-
7.04 
year 
follow-
up 
period 
Data 
analysis 
by Zhang 
et al./ 
2011 
Patients 
who 
underwent 
radiocontra
st 
procedures 
and were 
enrolled in 
randomized
, controlled 
trials 
Meta-analysis 
of randomized, 
controlled trials 
370 patients 
received statins 
prior to contrast 
procedures 
381 patients 
did not 
receive 
statins prior 
to their 
contrast 
procedures 
Statin use was not 
associated with a 
significant decrease 
in the incidence of 
contrast-induced 
nephropathy 
Some evidence 
exists that statin 
pretreatment may 
slightly decrease 
2.7 
days to 
10.6 
month 
pretreat
ment 
period; 
One-
month 
follow-
up 
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N=751 
serum creatinine 
levels in patients 
undergoing 
radiocontrast 
procedures 
period 
The findings of a study conducted by Layton et al. (2013), outlined in Table 2, 
supported the use of statins prior to coronary artery bypass grafting (CABG) surgery, 
since these medications may decrease the risk of AKI postoperatively. For this study, the 
researchers analyzed health care claims from large, employer-based and Medicare 
databases for the presence of a protective impact on the kidneys from statin therapy. 
Patients who were undergoing CABG surgery were selected as the sample group. The 
researchers found a very significant decrease in the incidence of AKI for patients who 
underwent statin therapy and consequently asserted that statins can protect the renal 
system for patients undergoing CABG surgery. Layton et al. (2013) theorized that the 
results would probably be similar for other types of surgery. 
Brunelli et al. (2012) published the findings of their retrospective analysis of a 
cohort of 98,939 patients, 10,779 of whom received preoperative statin therapy before 
cardiac, thoracic, or vascular surgery. As shown in Table 2, this preoperative statin use 
was particularly advantageous in preventing renal damage in patients who underwent 
vascular surgery and least advantageous to patients who underwent cardiac surgery. 
Brunelli et al. (2012) therefore concluded that preoperative statin use might have the 
potential to decrease the incidence of AKI. 
Luk et al. (2010) performed a prospective cohort study on the effects of statin use 
for 5,264 patients in China with type II diabetes mellitus (DM) over a nine-year period. 
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As outlined in Table 2, the study disclosed that the incidence of renal dysfunction 
decreased by 68% in patients who received statin therapy. The researchers consequently 
asserted that statin use might lower the risk of renal dysfunction and nephropathy related 
to type II DM (Luk et al., 2010).  
In an attempt to study the incidence of contrast-induced nephropathy in statin 
users, Zhang et al. (2011) conducted a meta-analysis of available data on randomized, 
controlled trials of patients who received statin therapy prior to radiocontrast studies. The 
results of the four selected trials, displayed in Table 2, revealed a lack of evidence that 
statin pretreatment before contrast procedures could decrease the incidence of contrast-
induced nephropathy. There was, however, some evidence that statin therapy might cause 
a slight decrease in serum creatinine levels. The researchers concluded that statins may 
help prevent nephropathy related to contrast dye used in radio-contrast studies, although 
more research is necessary before this practice is considered evidence-based.  
Statin Use in Renal Patients 
The initiation of statin therapy in patients with pre-existing renal dysfunction is 
laden with controversy. Several recent studies have led researchers to theorize that statins 
are actually not always very effective in lowering lipids in patients with all stages of 
CKD, including both dialysis patients and patients who do not require dialysis. Some 
studies have also concluded that since the nature of statin therapy requires that it be used 
for chronic treatment of hypercholesterolemia, the risks may not outweigh the benefits 
for patients with preexisting renal problems because long-term statin therapy increases 
the risks of myopathy leading to renal dysfunction.  
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A meta-analysis of randomized, controlled studies by Nikolic et al. (2013) found 
that the cardiovascular benefits of statins, which include influencing C-reactive protein 
levels, require that long-term therapy be maintained; unfortunately, such long-term 
therapy also significantly increases the risk of myopathy, which can lead to renal 
dysfunction, AKI, and possibly CKD. Nikolic et al. (2013) analyzed trials involving CKD 
patients who received statin therapy from 1966 to May 2012. Their final review 
incorporated the results of sixteen trials and 3,594 subjects. The trial findings showed a 
statistically significant decrease in total cholesterol, triglycerides, and LDL levels for 
early-stage CKD patients who took statins. Patients who took statins for a longer duration 
had even greater benefits related to the prolonged therapy. Dialysis patients had less 
significant decreases in the levels of these independent cardiovascular risk factors. The 
researchers stated that for these patients, the magnitude of total cholesterol and LDL was 
lower and triglycerides actually had a modest increase. When patients received short-term 
statin therapy, they were more likely to have increased HDL levels with an average 
increase of 0.7 mg/dL. In contrast, patients who received long-term statin therapy were 
likely to experience an average reduction of 2.4 mg/dL.  
As a result of their meta-analysis, Nikolic et al. (2013) concluded that patients 
who are not on dialysis are likely to experience significant lipid profile changes, whereas 
patients on dialysis may not experience statistically significant lipid profile changes; non-
dialysis patients also generally experience improved outcomes related to longer-term 
therapy, whereas dialysis patients actually have surprisingly decreased effectiveness 
related to longer-term therapy; perhaps this means that dialysis patients who wish to 
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receive the cardiovascular benefits of statin therapy should only receive the statins for a 
very short duration (Nikolic et al., 2013).  
While controversy still prevails over the effectiveness of statins at lowering lipids, 
there is a small amount of recent research that seems to indicate that in some cases of 
renal dysfunction, statins may not cause a therapeutic decrease in the risk for 
cardiovascular events, even if they may lower lipids. These studies raise the question of 
whether statin therapy is worthwhile, since it may increase the patient’s risk of 
progressive renal dysfunction without truly having a therapeutic benefit on the patient’s 
cardiovascular health. 
Natsuaki et al. (2012) detailed the results of the CREDO-Kyoto PCI/CABG 
Registry Cohort-2 study, which indicated statin usage does not significantly decrease the 
risk for major adverse cardiovascular events in patients with severe CKD. Statin use 
consistently related to a decreased risk of AKI, defined using serum creatinine changes as 
outlined by Acute Kidney Injury Network and Risk-Injury-Failure staging systems, and 
on the need for RRT. 
Olyaei, Greer, Santos, & Rueda (2011) completed a meta-analysis of the relevant 
literature that included the results of primary intervention studies and secondary 
intervention studies. Studies included the Study of Heart and Renal Protection (SHARP 
trial), described in Table 3, and the Incremental Decrease in Endpoints through 
Aggressive Lipid Lowering (IDEAL) trial, also outlined in Table 3. A Study to Evaluate 
the Use of Rosuvastatin in Subjects on Regular Hemodialysis (AURORA trial), which is 
outlined in Table 4, was also analyzed. Olyaei et al. (2011) asserted that patients in all 
stages of CKD are more likely to develop myalgia, myopathy and rhabdomyolysis from 
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statin therapy than patients who do not have some form of renal dysfunction; this study 
also concluded that CKD patients who are taking statins to lower their cholesterol should 
receive the lowest possible dose (Olyaei et al., 2011). 
The question remains: if myopathy and renal damage are valid concerns for those 
taking statins, how can healthcare providers advocate for their patients’ safety? In a 
recent article depicting their retrospective research study, Sai et al. (2013) advocated a 
standardized detection algorithm, which would allow physicians and other healthcare 
providers to detect statin-induced myopathy (SIM) based on the electronic medical record 
(EMR). The researchers collected data from the EMRs of 5,109 patients who had taken 
statins. They monitored the EMRs for changes including increased creatine kinase (CK) 
and were able to accurately detect five cases of suspected SIM (Sai et al., 2013). Such an 
algorithm may make it possible for conditions such as rhabdomyolysis to be diagnosed 
earlier than they would be otherwise, so they can be treated earlier and cause less long-
term damage to the renal system. 
Possible Effectiveness of Statin Therapy in Renal Patients 
Some studies of statin therapy in renal patients suggest that the benefits of statin 
therapy are significant enough to warrant statin use even in patients with various types of 
renal dysfunction. Among these, the Study of Heart and Renal Protection (SHARP trial) 
and Incremental Decrease in Endpoints through Aggressive Lipid Lowering (IDEAL 
trial) stand out as the most prominent clinical trials. The IDEAL trial, in particular, which 
was published in 2010, is still held up as a relevant research study in the discussion of 
statin therapy in renal patients. Below, Table 3 outlines the results of various studies, 
describing the data collection methods and the findings.  
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Table 3   Studies that suggest the effectiveness of statins in lowering cardiovascular risk for 
patients with renal dysfunction 
Study/ 
Year 
Population Intervention/ 
Methods 
Comparison Outcome Time 
The 
SHARP 
trial/ 
2011 
Patients with 
preexisting CKD 
and no known 
history of MI or 
coronary 
revascularization 
33% of total 
study population 
was receiving 
maintenance HD 
or PD 
N=9,270; 
40-70+ years; 
37% female 
Randomized, 
double-blind 
study  
4,650 
patients 
received a 
combination 
of 
simvastatin 
plus 
ezetimibe 
Control 
group of 
4,620 
patients 
received a 
matching 
placebo 
The experimental 
group had a 17% 
reduction in major 
atherosclerotic 
events  
There were no 
statistically 
significant 
differences between 
the results of 
participants on 
dialysis and those 
who were not on 
dialysis 
4-9 
year 
follow
-up 
period 
The 
IDEAL 
trial/ 
2005 
Patients with 
history of MI 
who underwent 
statin therapy for 
elevated serum 
cholesterol levels 
between 1999 
and 2005 
N=8,888; 
52-71 years; 
19% female 
Open-label, 
blinded, end-
point, 
randomized, 
controlled 
trial 
4,439 
patients 
received 80 
mg 
atorvastatin 
daily 
Comparison 
group of 
4,449 
patients 
received 20 
mg 
simvastatin 
daily 
Atorvastatin users 
had lower mean 
LDL levels than 
simvastatin users 
898 atorvastatin 
users experienced a 
coronary event 
during therapy, 
versus 1,059 
simvastatin users 
Media
n 4.8-
year 
follow
-up 
period 
The 
CREDO
-Kyoto 
PCI/CA
BG 
Registry 
Cohort-
2/ 
2012 
Patients with 
advanced CKD 
undergoing 
coronary 
revascularization 
N=14,706; 
53-75 years; 
28% female 
Retrospectiv
e cohort 
study 
7,228 
patients 
received 
statin therapy 
Control 
group of 
7,478 
patients did 
not receive 
statin 
therapy 
Statin users without 
CKD and with mild 
CKD had a 
significantly 
decreased incidence 
of major adverse 
cardiovascular 
events  
There was no 
significant risk 
699-
1,245 
day 
follow
-up 
period 
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decrease in patients 
with severe CKD or 
HD patients 
The 
SWEDE
HEART 
Registry 
Study/ 
2011 
Survivors of MI 
178 patients 
received dialysis 
prior to 
admission 
N=42,814 
Patients 
received 
statins at 
discharge 
from MI-
hospitalizatio
n 
Control 
group of 
patients did 
not receive 
statins at 
discharge 
Statin users with 
stages 2-4 of renal 
insufficiency had 
improved one-year 
survival rates 
Follo
w-up 
period 
Baigent et al. (2011) detailed the findings of the randomized placebo-controlled 
study known as the SHARP trial. The SHARP trial studied 9,270 patients with CKD with 
no known history of MI or coronary revascularization who received either daily doses of 
simvastatin 20 mg plus ezetimibe 10 mg or a matching placebo. 4,650 patients received 
the combination-drug, whereas 4,620 patients received a placebo. Researchers followed 
up with these patients after an average period of 4.9 years since the beginning of the trial 
to monitor for the occurrence of a first-time major atherosclerotic event, which was 
predefined by the study as a nonfatal myocardial infarction or coronary death, non-
hemorrhagic stroke, or any arterial revascularization procedure. Patients who received the 
simvastatin-ezetimibe combination experienced a 17% proportional reduction in major 
atherosclerotic events. Only 131 of the patients who took the simvastatin-ezetimibe 
combination medication experienced non-hemorrhagic stroke, as compared to 174 of the 
patients who took the placebo. Likewise, only 284 patients who received simvastatin-
ezetimibe therapy required arterial revascularization procedures as opposed to 352 of the 
patients who received the placebo. Baigent et al. (2011) therefore concluded simvastatin 
effectively reduced the risk of cardiovascular events in CKD patients when paired with 
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ezetimibe; these researchers therefore recommend the use of this particular statin 
combination drug for lowering cholesterol in patients with CKD.  
The findings from the SHARP trial are highly respected in the medical 
community and have integrated themselves in many cases into evidence-based practice 
(EBP) related to statin therapy. A systematic review and meta-analysis by Palmer et al. 
(2012) asserted that SHARP had a low risk of reporting bias, which reaffirms its 
credibility. In their discussion, however, Palmer et al. pointed out that dialysis patients 
who receive statins do not have a clear clinical reduction in major cardiovascular events, 
a fact that appears to contradict SHARP’s findings (Palmer et al., 2012).  
Numerous articles and reviews have been published on the findings from the 
SHARP trial, with different conclusions made in each case. Auer et al. (2014) recently 
analyzed the findings from the SHARP trial and came to the conclusion that there is a 
need for further research regarding statin-caused myopathy. They reiterated the concern 
that statin-related myopathy and renal dysfunction will only increase as more and more 
people receive statin therapy (Auer et al., 2014). In contrast, Jenkins and Goldsmith 
(2012) published an analysis of the SHARP trial that concluded the benefits of statin 
therapy warrant that CKD patients should undergo prophylactic statin therapy, regardless 
of whether their LDL cholesterol levels are high, since CKD patients are inherently 
predisposed to atherosclerosis and cardiovascular events. An analysis of the SHARP trial 
by Holme et al. (2011) suggested that in CKD patients statin therapy may decrease risk 
for some particular types of cardiovascular events, while not decreasing the risk of major 
coronary events; in contrast, statin therapy in non-CKD patients decreases the risk for 
major coronary events, as well as all other cardiovascular events except stroke.  
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Bae et al. (2012) performed a retrospective cohort study that included the analysis 
of 12,636 patients with acute myocardial infarction (AMI) in the Korea AMI Registry 
from 2005 to 2008. Of the patients in the registry, 93% had coronary angiography and 
91% of the patients who had coronary angiography had percutaneous coronary 
intervention (PCI) as well. This study revealed that patients who took beta-blockers, 
angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers 
with statins had a significantly lower risk of major adverse cardiac events in the one-
month and one-year follow-up periods. According to the findings of this study, statins 
might effectively decrease risk for major adverse cardiovascular events; this study also 
asserted that patients’ estimated glomerular filtration rate (eGFR) can be used as an 
indicator of their risk for mortality related to cardiovascular events (Bae et al., 2012).  
In 2011, Szummer et al. completed a retrospective cohort study that confirmed 
statin therapy after a MI is effective in decreasing the incidence of death from 
cardiovascular events and in protecting against renal dysfunction and failure from AKI 
and CKD. The researchers analyzed data from the national SWEDEHEART Registry 
related to 42,814 consecutive MI survivors who did not take statin therapy prior to 
hospitalization for their MIs. They found that patients in the early stages of CKD had a 
significant decrease in their overall mortality. The study published by Szummer et al. 
(2011) also indicated that statins might have the potential for improving the one-year 
survival rate of patients who are in stages 2-4 of kidney failure.  
Lim et al. (2012) conducted a study that supported the use of statins in patients 
with various types of renal dysfunction including CKD, since this study found statin 
therapy improved outcomes in CKD patients. The researchers studied a retrospective 
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cohort of 12,853 patients with AMI. They divided the cohort into four different groups: 
those who did not have any form of renal dysfunction and received statins, those who 
neither received statin therapy nor had renal dysfunction, those who both received statin 
therapy and had renal dysfunction, and those who had renal dysfunction but did not have 
renal dysfunction. The researchers then analyzed the separate groups for the primary end 
points of death and hospitalization complications, as well as secondary end points of 
MACE during the one-year post-AMI follow-up period. The study revealed that both 
patients with renal dysfunction and patients who did not have renal dysfunction 
experienced a decrease in the incidence of MACE during the follow-up period. Lim et al. 
(2012) therefore concluded that statin therapy could be beneficial for both patients with 
and without renal dysfunction. One limitation of this study is the fact that renal 
dysfunction was not clearly defined and may have only included patients in the very early 
stages of CKD, which would have impacted the results of the study.   
A systematic review and meta-analysis of various studies with CKD patients who 
took statins revealed some interesting findings. Palmer et al. (2012) discussed the 
findings of trials such as SHARP, AURORA, and 4D (Deutsche Diabetes Dialyse 
Studie). The researchers concluded that based on the latest research findings, statin 
therapy in CKD patients who are in the early stages of the disease and do not yet require 
dialysis can reduce cardiovascular events and mortality (Palmer et al., 2012).  
Most of the reviewed studies agreed that although statin use may potentially be 
helpful for patients in stages 2-4 of CKD, patients on dialysis or other forms of renal 
replacement therapy (RRT) may derive little to no cardiovascular benefit from statin use 
and may in fact do themselves more harm than good. 
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Possible Ineffectiveness of Statin Therapy in Renal Patients 
Although some research seems to support statin therapy’s efficacy and safety for 
patients with renal impairment, other studies are not so supportive. At any rate, the 
overwhelming majority of studies have suggested that patients with ESRD, and 
particularly those on HD, might not experience the desired effects of these drugs. Also, 
the risks of causing a preexisting renal dysfunction to progress further may outweigh the 
benefits of statin therapy for patients who may not even have ESRD but have some level 
of renal impairment. Below, Table 4 describes the various studies that suggest statin 
therapy may be ineffective in patients with renal dysfunction, as well as the data-
collecting methods and study outcomes. 
Table 4   Studies that suggest statins are ineffective in lowering cardiovascular risk for 
patients with renal dysfunction 
Study/ 
Year 
Population Intervention/ 
Methods 
Comparison Outcome Time 
The 
AURORA 
trial/ 
2009 
Patients 
with ESRD 
who had 
received 
routine HD 
for at least 
three 
months 
N=2,776 
50-80 years 
38% 
female 
Randomized, 
double-blinded 
placebo-
controlled 
multicenter trial 
study 
Patients in the 
experimental 
group received 
rosuvastatin as 
primary 
prevention 
against a major 
cardiovascular 
event 
Patients in 
the control 
group 
received a 
placebo 
Experimental group 
had 43% reduction in 
LDL-C level and 
27% reduction in 
total cholesterol 
levels  
No statistically 
significant decrease 
in the incidence of a 
major cardiovascular 
event (defined as 
nonfatal MI, nonfatal 
stroke, or death 
related to 
cardiovascular 
disease) 
396 rosuvastatin 
users had a major 
Three-
year 
follow
-up 
period 
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cardiovascular event; 
408 placebo users 
had a major 
cardiovascular event 
The 4D 
Study 
(Deutsche 
Diabetes 
Dialyse 
Studie)/ 
2005 
Patients 
with type 2 
diabetes 
mellitus 
who had 
received 
HD for 
more than 
two years 
Baseline 
cholesterol 
was 
between 80 
and 90 
N=1,255 
Randomized, 
multi-centered, 
double-blinded, 
placebo-
controlled 
prospective 
study 
619 patients 
received 
atorvastatin 
636 patients 
received a 
placebo 
There was no 
significant reduction 
in the risk of major 
cardiovascular events 
Two-
year 
follow
-up 
period 
Risks versus Benefits of Statin Use in Renal Patients 
Much debate exists regarding the safety and efficacy of the statin HMG-CoA 
Reductase Inhibiting medications in relation to the kidneys. An issue of particular 
concern is the question of whether these medications may potentially protect the kidneys 
from damage and thereby slow the progression of CKD, possibly increasing longevity. 
Another area of ambiguity is that of the effectiveness of these medications in lowering 
cholesterol and preventing adverse cardiovascular events for patients with various forms 
of renal dysfunction, including AKI and CKD. Based on the evidence that is currently 
available, it is safe to say that statin usage may have limited safety and efficacy in 
treating hyperlipidemia in patients with renal dysfunction 
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Ethical Considerations 
Although the researchers obtained informed consent before conducting the study, 
the SHARP and AURORA trials, like so many other trials, raise several ethical 
considerations; namely, is it ethical for researchers to experiment with patients’ lives by 
giving them a placebo–and exempting them from getting what is more likely an effective 
treatment? This question is not an easy one, but the researchers for any study should 
consider it before proceeding with the study. Certain study designs may also help 
eliminate the ethical dilemma raised by studies that provide participants with a placebo 
instead of an equally effective therapy. According to Sullivan (2011), a trial that utilizes 
an equally effective medication considered the standard of care instead of a placebo is 
called an active-controlled trial. An active-controlled trial would be ethically appropriate 
in cases of hypercholesterolemia in which medication is necessary; patients in the control 
group would still receive treatment for their hypercholesterolemia while serving as the 
comparison for groups receiving the statin medications.  
Method 
This integrative review incorporated a search of several nursing and medical 
databases, including CINAHL and PubMed, for randomized controlled trials and meta-
analyses of recent trials. As Table 5 shows, the search used the key words: statins, HMG-
CoA Reductase Inhibitors, renal insufficiency, AKI, rhabdomyolysis, statin-caused 
myopathy, renal failure, and CKD. Phrases paired various types of renal insufficiency 
with the two names used to identify the statin drugs: statins and HMG-CoA Reductase 
Inhibitors. The most productive searches were those using the phrases: CKD and statins, 
CKD and HMG-CoA Reductase Inhibitors, AKI and statins, AKI and HMG-CoA 
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Reductase Inhibitors, renal insufficiency and statins, renal insufficiency and HMG-CoA 
Reductase Inhibitors, rhabdomyolysis and statins, and rhabdomyolysis and HMG-CoA 
Reductase Inhibitors. A total of 563 articles surfaced. Of the articles that surfaced, only 
30 articles fit the two-fold selection criteria of patients with CKD who have taken statins 
or patients who have taken statins and developed AKI, which later led to increased risk 
for CKD.  
 
 
Key Search Terms 
(2010-2015) 
Table 5   Search Results 
 
Cochrane 
Review 
 
OVID 
EBSCO host 
(CINAHL; 
Nursing & 
Allied Health 
Collection) 
 
Pub 
Med 
 
Total 
 
Relevant 
Articles 
HMG-CoA Reductase 
Inhibitor, statin, renal 
insufficiency, renal 
failure, chronic kidney 
disease, acute kidney 
injury, statin-caused 
myopathy, 
rhabdomyolysis 
 
8 
 
224 
 
247 
 
84 
 
563 
 
30 
 
Study Selection 
 Studies were selected based on their relevance to the topic of statins and their 
relationship to renal impairment and CKD. Studies of patients with CKD who used 
statins were included, as were studies of patients with AKI who used statins. Studies of 
patients who developed renal insufficiency, AKI, or CKD with a possible relation to the 
use of statins were also included. Studies that discussed statin therapy apart from renal 
dysfunction were excluded. Studies of statin use in patients who did not have renal 
dysfunction, either prior to statin use or related to statin-caused myopathy were excluded 
STATINS AND KIDNEY FAILURE 28 
as well. Studies with a sample size of less than 40 were also excluded. Data extraction 
occurred based on articles that depicted the following outcomes: rhabdomyolysis after 
statin therapy in CKD patients, myopathy after statin therapy in patients with renal 
impairment, AKI incidence related to statin therapy, AKI prevention related to statin 
therapy and reduction in cardiovascular disease-related mortality in CKD patients after 
statin therapy.  
Data Analysis  
Studies were analyzed and divided into groups based on whether the findings fit 
into one of the following categories: statins having a positive effect on patients’ renal 
function, statins having a negative effect on patients’ renal function, statins decreasing 
the risk of cardiovascular disease and/or mortality in patients with renal impairment, 
statins having no effect on the risk of cardiovascular disease and/or mortality in patients 
with renal impairment and statins increasing the risk of cardiovascular disease and/or 
mortality in patients with renal impairment. None of the analyzed studies suggest that 
statin therapy increases the risk of cardiovascular disease and mortality in patients with 
impaired renal function; therefore, this category was not included in the final integrative 
review.  
Implications for Nursing Practice 
An important consideration for nurses is the possibility of a reliable algorithm for 
detecting myopathy related to statin use, as discussed earlier. Such a tool may prove very 
useful in preventing serious renal damage before it occurs. If an algorithm becomes 
available, nurses should learn how to use it in daily practice so they can integrate this 
knowledge into their physical assessments of patients receiving statins and hopefully help 
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to detect myopathies related to statin usage. Evidence-based practice can incorporate the 
use of a warning system in the EMR. An EMR warning system would be easy for nurses 
and other healthcare providers to use, while tracking CK levels and perhaps including 
renal-specific indicators such as creatinine clearance rate and blood urea nitrogen (BUN). 
A well-designed warning system might also incorporate basic laboratory data such as the 
complete blood count (CBC) and symptoms of myopathy such as myalgia, nausea and 
vomiting, fever, and tachycardia (Sai et al., 2013). With a proper warning system in the 
EMR, nurses could play a vital part in monitoring for renal injury and dysfunction while 
continuing to carry out their routine patient assessments and interventions. While an 
EMR warning system for statin-induced myotoxicity and renal dysfunction has not yet 
been extensively developed and implemented, healthcare providers may be able to design 
one in the near future that could help prevent needless renal dysfunction and morbidity.  
Nurses also have a responsibility to educate patients about the medications they 
receive. Patient education should include teaching about the unique impact these 
medications may have on individual patients because of personal idiosyncratic factors 
such as CKD. Patients with CKD should learn that there are certain inherent risks if they 
choose to begin therapy with statin drugs. As shown in this integrative review, patients 
with preexisting renal dysfunction who take statin drugs may be more likely to 
experience further progression of their already-present renal dysfunction. There does not 
appear to be a difference in the impact of various statins on renal function. Although 
CKD and renal impairment does not contraindicate the use of statin therapy to treat 
hypercholesterolemia, healthcare providers should be prepared to educate these patients 
about the risks versus the benefits of statin therapy.  
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Patients with renal impairment may also require dosage modification due to their 
impaired renal function, and nurses, as the healthcare providers who perform the last 
safety check prior to medication administration, need to be aware of this so that they will 
know to advocate for their patients and question an inappropriate dose for a patient with 
renal impairment. Since the nurses are often the last ones to see a medication’s dosage 
before it is given and they are often the ones giving medications such as the statin 
medications in the hospital setting, it is important for them to know what the appropriate 
dosages are and how they would be modified in the case of renal dysfunction. Nurses 
should be aware of the risks of statin use for patients with CKD and other forms of renal 
dysfunction and they should be prepared to inform patients with renal dysfunction of 
these risks.  
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